Department of Gynecology and Obstetrics, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium
Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium.
Anticancer Res. 2019 Nov;39(11):5953-5962. doi: 10.21873/anticanres.13800.
BACKGROUND/AIM: The presence of ascites in ovarian cancer patients is considered a negative prognostic factor. The underlying mechanisms are not clearly understood.
The amount of ascites was evaluated, preferably, using diffusion-weighted MRI at primary diagnosis in a retrospective cohort of 214 women with ovarian cancer, in an ordinal manner (amount of ascites: none, limited, moderate, abundant). In a prospective cohort comprising 45 women with ovarian cancer, IL-10 (interleukin), VEGF (vascular endothelial growth factor), TGF-β (transforming growth factor) and CCL-2 [chemokine (C-C) motif ligand 2] were measured at diagnosis (and at interval debulking, when available).
Gradually increasing amounts of ascites were correlated significantly, even after correction for FIGO stage, with reduced survival (p<0.0001) and stronger immunosuppression (IL10 and VEGF). Neoadjuvant chemotherapy reduced immunosuppression, which was observed as a reduction in CCL-2, IL-10 and VEGF.
The amount of ascites is an independent predictor of survival and correlates with increased immunosuppression.
背景/目的：卵巢癌患者出现腹水被认为是一个负面的预后因素。其潜在机制尚不清楚。
在一个包含 214 名卵巢癌患者的回顾性队列中，我们优选地在初次诊断时使用扩散加权 MRI 对腹水的量进行评估，采用序数方式（腹水的量：无、有限、中等、大量）。在一个包含 45 名卵巢癌患者的前瞻性队列中，我们在诊断时（以及在间隔减瘤术时，如果有的话）测量了白细胞介素 10（IL-10）、血管内皮生长因子（VEGF）、转化生长因子-β（TGF-β）和趋化因子（C-C）基序配体 2（CCL-2）。
即使在纠正了 FIGO 分期后，腹水逐渐增加与生存时间缩短（p<0.0001）和更强的免疫抑制（IL10 和 VEGF）显著相关。新辅助化疗降低了免疫抑制，这表现为 CCL-2、IL-10 和 VEGF 的减少。
腹水的量是生存的独立预测因素，并与增加的免疫抑制相关。
